Recent Updates
Recently added Catalysts
XENE

Xenon Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference

Key Takeaway: BURNABY, British Columbia, June 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and present at the 2022 Jefferies Healthcare Conf
Price reaction · baseline $26.35 (2022-05-31 close) · hit after-hours · clean, no other XENE news in the window
day 0 close · peak
+1.3%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+56%
120-day peak, hindsight
Typical move
14.4%
average across 4 past catalysts
Cash runway
~39 mo
Minimal dilution risk
Lead asset
XPF-001
Phase 1 · Primary Erythromelalgia

Full Press Release Details

BURNABY, British Columbia, June 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and present at the 2022 Jefferies Healthcare Conference to be held June 8-10, 2022 in New York, NY.
Company Presentation Details:
A webcast of the company presentation will also be broadcast live on the “Investors” section of Xenon's website at investor.xenon-pharma.com. When available, webcasts will be posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Xenon Pharmaceuticals Inc.
Last updated: Jun 1, 2022